Table 1 Clinical characteristics of patients
From: The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia
Characteristics | Patients, No. (%) | P | |
|---|---|---|---|
Grade < 2 pneumonitis (N = 106) | Grade ≥ 2 pneumonitis (N = 42) | ||
Age | Â | Â | 0.311 |
 ≤ 65 | 70 (66.0%) | 24 (57.1%) |  |
 > 65 | 36 (34.0%) | 18 (42.9%) |  |
Sex | Â | Â | 0.594 |
Male | 87 (82.1%) | 36 (85.7%) | Â |
Female | 19 (17.9%) | 6 (14.3%) | Â |
Smoke | Â | Â | 0.921 |
Smoker | 47 (44.3%) | 19 (45.2%) | Â |
Non-smoker | 59 (55.7%) | 23 (54.8%) | Â |
KPS | Â | Â | 0.991 |
 < 80 | 5 (4.7%) | 2 (4.8%) |  |
 ≥ 80 | 101 (95.3%) | 40 (95.2%) |  |
Stage | Â | Â | 0.638 |
I–II | 2 (1.9%) | 2 (4.8%) |  |
III | 63 (59.4%) | 25 (59.5%) | Â |
IV | 41 (38.7%) | 15 (35.7%) | Â |
Histology | Â | Â | 0.254 |
Adenocarcinoma | 50 (47.2%) | 20 (47.6%) | Â |
Squamous cell carcinoma | 52 (49.1%) | 22 (52.4%) | Â |
Other | 4 (3.8%) | 0 (0.0%) | Â |
ICIs + TRT |  |  | 0.259 |
Concurrent | 17 (14.3%) | 2 (24.1%) | Â |
Sequential | 102 (85.7%) | 22 (75.9%) | Â |
RT Dose | Â | Â | 0.991 |
 < 50 | 16 (15.1%) | 6 (14.3%) |  |
50–60 | 42 (39.6%) | 17 (40.5%) |  |
 ≥ 60 | 48 (45.3%) | 19 (45.2%) |  |
Anlotinib | Â | Â | 0.016 |
Yes | 26 (24.5%) | 3 (7.1%) | Â |
No | 80 (75.5%) | 39 (92.9%) | Â |
Bevacizumab | Â | Â | 0.341 |
Yes | 8 (7.5%) | 6 (14.3%) | Â |
No | 98 (92.5%) | 36 (85.7%) | Â |